Ozelle debuts O-Cyte 1 hematology analyzer at MEDICA 2026
Ozelle has unveiled the O-Cyte 1, a new diagnostic tool designed to provide cellular imaging for blood analysis following abnormal complete blood count results.

Medical technology firm Ozelle introduced the O-Cyte 1 hematology analyzer this week at the MEDICA 2026 trade fair in Düsseldorf. The device is designed to assist clinicians by providing detailed cellular imaging when standard complete blood count (CBC) tests flag abnormal findings.
By automating the visual assessment of blood cells, the system aims to streamline the diagnostic workflow for laboratories that would otherwise rely on manual microscopy for follow-up testing. This automated imaging capability seeks to reduce the time required to investigate ambiguous hematological results.
The launch comes as diagnostic laboratories face increasing pressure to balance diagnostic accuracy with rapid turnaround times. The O-Cyte 1 represents Ozelle’s entry into the automated digital morphology market, an area where competitors are also increasing efforts to integrate AI and automated imaging into standard laboratory practice.
Ozelle expects the O-Cyte 1 to be available for clinical deployment in selected markets starting in early 2027.